% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{deBraud:274418, author = {F. de Braud and C. Dooms and R. S. Heist and C. Lebbe and M. Wermke and A. Gazzah and D. Schadendorf$^*$ and P. Rutkowski and J. Wolf and P. A. Ascierto and I. Gil-Bazo and S. Kato and M. Wolodarski and M. McKean and E. Muñoz Couselo and M. Sebastian and A. Santoro and V. Cooke and L. Manganelli and K. Wan and A. Gaur and J. Kim and G. Caponigro and X.-M. Couillebault and H. Evans and C. D. Campbell and S. Basu and M. Moschetta and A. Daud}, title = {{I}nitial {E}vidence for the {E}fficacy of {N}aporafenib in {C}ombination {W}ith {T}rametinib in {NRAS}-{M}utant {M}elanoma: {R}esults {F}rom the {E}xpansion {A}rm of a {P}hase {I}b, {O}pen-{L}abel {S}tudy.}, journal = {Journal of clinical oncology}, volume = {41}, number = {14}, issn = {0732-183X}, address = {Alexandria, Va.}, publisher = {American Society of Clinical Oncology}, reportid = {DKFZ-2023-00585}, pages = {2651-2660}, year = {2023}, note = {2023 May 10;41(14):2651-2660}, abstract = {No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant melanoma is currently available.In this phase Ib escalation/expansion study (ClinicalTrials.gov identifier: NCT02974725), the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF/CRAF protein kinases inhibitor, were explored in combination with trametinib in patients with advanced/metastatic KRAS- or BRAF-mutant non-small-cell lung cancer (escalation arm) or NRAS-mutant melanoma (escalation and expansion arms).Thirty-six and 30 patients were enrolled in escalation and expansion, respectively. During escalation, six patients reported grade ≥3 dose-limiting toxicities, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1). The recommended doses for expansion were naporafenib 200 mg twice a day plus trametinib 1 mg once daily and naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily. During expansion, all 30 patients experienced a treatment-related adverse event, the most common being rash $(80\%,$ n = 24), blood creatine phosphokinase increased, diarrhea, and nausea $(30\%,$ n = 9 each). In expansion, the objective response rate, median duration of response, and median progression-free survival were $46.7\%$ $(95\%$ CI, 21.3 to 73.4; 7 of 15 patients), 3.75 $(95\%$ CI, 1.97 to not estimable [NE]) months, and 5.52 months, respectively, in patients treated with naporafenib 200 mg twice a day plus trametinib 1 mg once daily, and $13.3\%$ $(95\%$ CI, 1.7 to 40.5; 2 of 15 patients), 3.75 $(95\%$ CI, 2.04 to NE) months, and 4.21 months, respectively, in patients treated with naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily.Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with NRAS-mutant melanoma. Prophylactic strategies aimed to lower the incidence of skin-related events are under investigation.}, cin = {ED01}, ddc = {610}, cid = {I:(DE-He78)ED01-20160331}, pnm = {899 - ohne Topic (POF4-899)}, pid = {G:(DE-HGF)POF4-899}, typ = {PUB:(DE-HGF)16}, pubmed = {pmid:36947734}, doi = {10.1200/JCO.22.02018}, url = {https://inrepo02.dkfz.de/record/274418}, }